PalCare Names Healthcare Veteran Lauren Wilson as Chief Revenue Officer to Lead Strategic Expansion

MILWAUKEE, Aug. 12, 2025 (GLOBE NEWSWIRE) — PalCare, a leader in nurse call and resident safety technology, proudly announces the appointment of Lauren Wilson as its Chief Revenue Officer. A 20-year healthcare executive with a reputation for driving transformation in aging services, Wilson joins PalCare to lead strategic growth, market expansion, and partner success during […]

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

(NASDAQ:PYPD), PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company“), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on PolyPid's Board

LRT Company Launches $20.55 Million All-Cash DST Offering Near Providence, R.I.

LRT Company, a land acquisition and real estate investment firm that specializes in complete land entitlements, ground lease financing and is a sponsor of Section 1031 exchange investment offerings, announced today that it has launched LRT Coventry RI DST. The all-cash, Regulation D private placement Delaware statutory trust offering seeks to raise $20.55 million in

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

(NASDAQ:ELTX), At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) induced by ELI-002 77% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses

Integer to Present at 2025 Wells Fargo Healthcare Conference on Sept. 4

(NYSE:ITGR), PLANO, Texas, Aug. 12, 2025 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced participation in the 2025 Wells Fargo Healthcare Conference, to be held Sept. 3 – 5, in Boston. Members of the Integer executive leadership team will participate in a fireside chat

SimpleTherapy Ranks No. 1234 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies

FRESNO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) — SimpleTherapy, a leading omnichannel care provider of musculoskeletal (MSK) and behavioral health care solutions, is proud to announce its inclusion in the 2025 Inc. 5000 list, a prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies

Holistic Wealth Advisors Announces Launch as Fully Independent RIA

CLIFTON PARK, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) — Holistic Wealth Advisors (HWA) is proud to announce its official launch as a fully independent, SEC-registered investment advisory firm. With over $350 million in client assets under management, HWA now operates as a stand-alone RIA–marking a new chapter for the firm and the clients it serves.

57 Confluent Health Physical and Occupational Therapists Receive Board-Certified Clinical Specialist Credential

LOUISVILLE, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) — Fifty-seven Physical and Occupational Therapists from Confluent Health's Partner Brands have achieved nationally recognized board certifications, a prestigious milestone that places them among the top musculoskeletal (MSK) professionals in the United States. These therapists join an elite group of clinicians representing less than 13% of the industry.

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

(NasdaqGM:SLXN), GRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the second quarter ended June 30, 2025, and provided an update on recent business developments. Recent Milestones

Bayvrio launches first-of-its-kind marketplace that provides healthcare payers with greater choice, flexibility, and control

Payers can choose from best-in-class solutions and suppliers to build, manage, and deliver pharmacy benefit and healthcare strategies tailored to their needs and goals Bayvrio, a provider of advanced technology and innovative, curated solutions to healthcare payers, today announced the launch of the Bayvrio Marketplace, a first-of-its-kind model that will change the way the industry

Scroll to Top